Alnylam Pharmaceuticals (ALNY) Retained Earnings (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Retained Earnings of -$24.9 million for Q1 2026, up 33.65% year-on-year from -$18.6 million in Q1 2025, and down 23.87% on a QoQ basis from -$20.1 million in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of Retained Earnings data on file, last reported at -$24.9 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 33.65% year-over-year to -$24.9 million; the trailing twelve-month figure through Mar 2026 stood at -$24.9 million (up 33.65% YoY), and the FY2025 full-year result was -$20.1 million, up 41.78% from the prior year.
- Retained Earnings for Q1 2026 stood at -$24.9 million, down from -$20.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$20.1 million in Q4 2025 and bottomed at -$7.1 billion in Q2 2024.
- The 5-year median for Retained Earnings is -$37.5 million (2025), against an average of -$1.3 billion.
- The widest annual swing landed in 2024, when Retained Earnings tumbled 19027.33%; it then surged 99.58% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$44.7 million in 2022, then sank by 15597.57% to -$7.0 billion in 2023, then surged by 99.51% to -$34.5 million in 2024, then soared by 41.78% to -$20.1 million in 2025, then slipped by 23.87% to -$24.9 million in 2026.
- The last three Retained Earnings figures came in at -$24.9 million (Q1 2026), -$20.1 million (Q4 2025), and -$21.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -622,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.89 Mn |
| Dec 31, 2025 | -20.10 Mn |
| Sep 30, 2025 | -21.78 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Mar 31, 2025 | -37.52 Mn |
| Dec 31, 2024 | -34.52 Mn |
| Sep 30, 2024 | -24.83 Mn |
| Jun 30, 2024 | -7.09 Bn |
| Mar 31, 2024 | -7.08 Bn |
| Dec 31, 2023 | -7.01 Bn |
| Sep 30, 2023 | -32.34 Mn |
| Jun 30, 2023 | -37.08 Mn |
| Mar 31, 2023 | -39.12 Mn |
| Dec 31, 2022 | -44.65 Mn |
| Sep 30, 2022 | -43.78 Mn |
| Jun 30, 2022 | -42.22 Mn |
| Mar 31, 2022 | -38.07 Mn |
| Dec 31, 2021 | -5.44 Bn |
| Sep 30, 2021 | -5.18 Bn |
| Jun 30, 2021 | -36.08 Mn |
| Mar 31, 2021 | -4.79 Bn |
| Dec 31, 2020 | -43.62 Mn |
| Sep 30, 2020 | -37.19 Mn |
| Jun 30, 2020 | -33.21 Mn |
| Mar 31, 2020 | -32.06 Mn |
| Dec 31, 2019 | -3.73 Bn |
| Sep 30, 2019 | -34.37 Mn |
| Jun 30, 2019 | -3.24 Bn |
| Mar 31, 2019 | -32.85 Mn |
| Dec 31, 2018 | -2.84 Bn |
| Sep 30, 2018 | -33.39 Mn |
| Jun 30, 2018 | -2.38 Bn |
| Mar 31, 2018 | -2.22 Bn |
| Dec 31, 2017 | -2.15 Bn |
| Sep 30, 2017 | -2.01 Bn |
| Jun 30, 2017 | -1.88 Bn |
| Mar 31, 2017 | -33.83 Mn |
| Dec 31, 2016 | -1.66 Bn |
| Sep 30, 2016 | -27.78 Mn |
| Jun 30, 2016 | -28.30 Mn |
| Mar 31, 2016 | -9.01 Mn |
| Dec 31, 2015 | 4.37 Mn |
| Sep 30, 2015 | -1.16 Bn |
| Jun 30, 2015 | -1.08 Bn |
| Mar 31, 2015 | -1.01 Bn |
| Dec 31, 2014 | 48.76 Mn |
| Sep 30, 2014 | -935.24 Mn |
| Jun 30, 2014 | 21.98 Mn |
| Mar 31, 2014 | -847.18 Mn |
| Dec 31, 2013 | 19.72 Mn |
| Sep 30, 2013 | -563.88 Mn |
| Jun 30, 2013 | -534.19 Mn |
| Mar 31, 2013 | -516.02 Mn |
| Dec 31, 2012 | -507.01 Mn |
| Sep 30, 2012 | -444.82 Mn |
| Mar 31, 2012 | -412.36 Mn |
| Dec 31, 2011 | -401.00 Mn |
| Sep 30, 2011 | -151,000.00 |
| Jun 30, 2011 | -246,000.00 |
| Mar 31, 2011 | -18,000.00 |
| Dec 31, 2010 | 714,000.00 |
| Sep 30, 2010 | -336.42 Mn |
| Jun 30, 2010 | -326.79 Mn |
| Dec 31, 2009 | 716,000.00 |